Listen
ENBREL (etanercept), anti-TNF
RHEUMATOLOGY - Focus
Opinions on drugs -
Posted on
Jul 06 2016
Reason for request
Extension of Inclusion
Second-line treatments in juvenileidiopathic arthritis (JIA) in case of insufficient response or intolerance to methotrexate.
- Two anti-TNFs, HUMIRA and ENBREL, which have Marketing Authorisation as a first-line treatment for the active polyarticular form of JIA now have Marketing Authorisation in other forms of the disease:
- the enthesitis-related form, from 6 years of age for HUMIRA and from 12 years of age for ENBREL.
- psoriatic arthritis from 6 years of age and extended oligoarthritis from 2 years of age, for ENBREL only.
- These are second-line treatments, prescribed in case of insufficient response or intolerance to methotrexate, reference long-term first line treatment.
Clinical Benefit
| Moderate |
- |
Clinical Added Value
| no clinical added value |
- |
Therapeutic use
|
- |
English version
Contact Us
Évaluation des médicaments
